Kenvue Stock (US49177J1025): Q1 2026 Earnings Set for May 7 Before Market Open

Kenvue Inc., the NYSE-listed consumer health giant, will release its first quarter 2026 financial results on May 7, 2026, before the market opens. U.S. investors can tune into the conference call for insights into sales of Tylenol, Neutrogena and other key brands.

Kenvue Inc. will announce its first quarter 2026 financial results before the market opens on May 7, 2026, according to the company release dated April 23, 2026. The consumer health company, listed on the NYSE under ticker KVUE with ISIN US49177J1025, operates in the U.S. and international markets through segments including Self Care, Skin Health and Beauty, and Essential Health.

As of April 29, 2026

By the AD HOC NEWS editorial team – specialist desk for consumer health stocks.

At a glance

• Name: Kenvue Inc.
• ISIN: US49177J1025
• Sector/industry: Consumer health
• Headquarters/country: United States
• Key markets: United States, Europe, Asia-Pacific
• Main revenue drivers: Self Care, Skin Health and Beauty, Essential Health
• Primary listing/trading venue: NYSE
• Trading currency: USD
• Latest quarterly results: Q4 2025 released February 18, 2026
• Next earnings date: May 7, 2026 before market open

How Kenvue makes money

Kenvue Inc. generates revenue primarily from consumer health products sold across three segments: Self Care, Skin Health and Beauty, and Essential Health, according to its company overview. The Self Care segment includes pain relief, cough and cold remedies, and digestive health products under brands such as Tylenol, Motrin, Benadryl, and Zyrtec.

Skin Health and Beauty features skincare and beauty items from brands like Neutrogena and Aveeno, while Essential Health covers oral care, women's health, and wound care with brands including Listerine and Band-Aid. These products are distributed in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America.

In 2024, the company reported revenue of $15.46 billion, a slight increase of 0.07% from $15.44 billion the prior year, with earnings of $1.03 billion. Kenvue positions itself as the world's largest pure-play consumer health company by revenue.

The key revenue and product drivers for Kenvue

The Self Care segment drives significant revenue through established brands like Tylenol for pain relief and Zyrtec for allergy treatment, contributing to the company's $15.46 billion in 2024 revenue. Skin Health and Beauty relies on Neutrogena skincare and Aveeno natural products, while Essential Health includes Listerine mouthwash and Johnson's Baby lines.

For full-year 2024, revenue grew marginally by 0.07% year-over-year to $15.46 billion, though earnings fell 38.10% to $1.03 billion. Investors await Q1 2026 results on May 7, 2026, for updates on these drivers amid U.S. consumer spending trends.

U.S. sales form a core part of Kenvue's business, given its headquarters in Summit, N.J., and NYSE listing, exposing it directly to American retail investor interest.

Industry trends and competitive position

The consumer health sector emphasizes over-the-counter remedies and personal care, with steady demand in areas like pain management and skincare. Kenvue's portfolio of trusted brands positions it strongly in these categories, operating globally but with heavy U.S. reliance.

Market dynamics include rising focus on natural ingredients and self-care products, aligning with Aveeno and Zarbee’s offerings. The company's scale as the largest pure-play player by revenue supports its competitive stance in a fragmented industry.

Trends toward e-commerce and direct-to-consumer channels also influence distribution, benefiting Kenvue's broad brand reach across pharmacies and online platforms.

Why Kenvue matters for U.S. investors

Kenvue trades on the NYSE in USD, providing straightforward access for U.S. retail investors via standard brokerage accounts. Its U.S. headquarters in Summit, N.J., and significant domestic revenue from brands like Tylenol make it a direct play on American consumer health spending.

SEC filings and quarterly earnings, such as the upcoming Q1 2026 release on May 7, 2026, offer transparency familiar to U.S. investors. The company's global operations include substantial U.S. market exposure, tying performance to local economic conditions like inflation and retail sales.

With a market cap around $33.6 billion, Kenvue represents a sizable option in the consumer staples space for diversified portfolios focused on defensive health products.

Which investor profile fits Kenvue stock — and which may not

Investors seeking exposure to stable consumer health brands with everyday demand may find alignment with Kenvue's business model, given its long-standing portfolio. Those interested in NYSE-listed firms with U.S.-centric operations often monitor such names for consistency across economic cycles.

Profiles favoring high-growth tech or cyclical sectors might look elsewhere, as Kenvue's focus on mature OTC products yields more predictable but slower expansion. Dividend-oriented investors could assess payout history alongside earnings releases like the one scheduled for May 7, 2026.

Overall, it suits those prioritizing brand strength and segment leadership over rapid revenue acceleration.

What analysts are saying about Kenvue stock

Wall Street's consensus on Kenvue stock is a Hold rating from 13 analysts, including one Strong Buy and twelve Holds, according to data referenced in market reports. Citigroup analyst Filippo Falorni maintained a Neutral rating on February 19, 2026, raising the price target to $20 from $18.

The mean price target stands at $19.09, with a high of $22, as noted in recent coverage. These views reflect evaluations post the Q4 2025 earnings on February 18, 2026.

Risks and open questions for Kenvue

Consumer health firms like Kenvue face risks from supply chain disruptions affecting product availability, particularly for imported ingredients in skincare lines. Regulatory scrutiny on OTC claims could impact marketing for brands like Zyrtec or Tylenol.

Competition in crowded categories, such as pain relief and oral care, pressures margins, as seen in the 38.10% earnings drop in 2024 despite flat revenue growth. Upcoming Q1 2026 results on May 7 will clarify if these trends persist.

Currency fluctuations from international sales also pose exposure for USD-reporting investors, alongside shifts in consumer preferences toward generics.

What investors can watch next

The Q1 2026 earnings release on May 7, 2026, before market open will provide updates on segment performance and full-year outlook. A conference call is typically held following such announcements for management commentary.

Investors may track post-earnings stock reaction and any guidance revisions, building on Q4 2025 results from February 18, 2026.

Next items to watch

• May 7, 2026: Q1 2026 earnings before market open

Bottom line

Kenvue's announcement of Q1 2026 results for May 7, 2026, draws attention from U.S. investors tracking NYSE-listed consumer health stocks. The release will shed light on performance across Self Care, Skin Health and Beauty, and Essential Health segments amid steady 2024 revenue of $15.46 billion. Market participants await details on brand sales and outlook from this pure-play leader.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.